Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VYGR
stocks logo

VYGR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.49M
+67.16%
-0.527
-10.63%
9.38M
+44.83%
-0.486
-8.36%
10.80M
+107.74%
-0.443
-22.31%
Estimates Revision
The market is revising Upward the revenue expectations for Voyager Therapeutics, Inc. (VYGR) for FY2025, with the revenue forecasts being adjusted by 11.98% over the past three months. During the same period, the stock price has changed by 2.59%.
Revenue Estimates for FY2025
Revise Upward
up Image
+11.98%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.64%
In Past 3 Month
Stock Price
Go Up
up Image
+2.59%
In Past 3 Month
Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.57 USD with a low forecast of 8.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.57 USD with a low forecast of 8.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.350
sliders
Low
8.00
Averages
13.57
High
25.00
Current: 4.350
sliders
Low
8.00
Averages
13.57
High
25.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $25
2025-11-12
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $25
2025-11-12
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Voyager Therapeutics to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones, the analyst tells investors in a research note. The company also advanced its NeuroShuttle non-viral delivery technology, with upcoming preclinical and trial data presentations expected to drive potential inflection points, the firm says.
Leerink
Outperform
to
NULL
downgrade
$12 -> $11
2025-11-10
Reason
Leerink
Price Target
$12 -> $11
2025-11-10
downgrade
Outperform
to
NULL
Reason
Leerink lowered the firm's price target on Voyager Therapeutics to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therapeutics reported Q3 results and provided pipeline updates, highlighting progress in Alzheimer's programs and its NeuroShuttle nonviral delivery platform, and the company remains on track for key milestones in 2026, including PET imaging data for VY7523 and an IND filing for siRNA therapy VY1706, the analyst tells investors in a research note.
Wedbush
Outperform
to
NULL
downgrade
$9 -> $8
2025-08-07
Reason
Wedbush
Price Target
$9 -> $8
2025-08-07
downgrade
Outperform
to
NULL
Reason
Wedbush lowered the firm's price target on Voyager Therapeutics to $8 from $9 and keeps an Outperform rating on the shares. The firm notes the quarterly update reported runway extension from mid-2027 to 2028 with end of Q2 total cash of $262M through restructuring and improving execution efficiency. There appears to be no impact on the pipeline, which in fact was recently further expanded when Voyager announced a fourth wholly owned GTx program that leverages a TRACER capsid to IV-deliver a bifunctional payload to decrease the expression of APOE in APOE4 carriers while increasing the expression of the protective variant APOE2. All other programs remain on track, Wedbush adds.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$30
2025-04-08
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$30
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$30
2025-03-13
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$30
2025-03-13
Reiterates
Strong Buy
Reason
Canaccord Genuity
Sumant Kulkarni
Strong Buy
Maintains
$14 → $12
2025-03-13
Reason
Canaccord Genuity
Sumant Kulkarni
Price Target
$14 → $12
2025-03-13
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on Voyager Therapeutics to $12 from $14 and keeps a Buy rating on the shares. The firm said they reported its 4Q24 results showing Operating expenses came in at $44.6M versus estimates of $43.0M, and collaboration revenue was $6.3M versus $10.0M estimate. Canaccord believes the delta in both was most likely driven by the timing of R&D activity, which can be difficult to predict.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Voyager Therapeutics Inc (VYGR.O) is -2.28, compared to its 5-year average forward P/E of -3.00. For a more detailed relative valuation and DCF analysis to assess Voyager Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.00
Current PE
-2.28
Overvalued PE
-0.45
Undervalued PE
-5.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.09
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.63
Undervalued EV/EBITDA
-5.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
10.85
Current PS
0.00
Overvalued PS
24.60
Undervalued PS
-2.90
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

VYGR News & Events

Events Timeline

(ET)
2025-11-10
08:10:56
Voyager Therapeutics anticipates sufficient cash to sustain operations through 2028.
select
2025-11-10
08:10:34
Voyager Therapeutics announces Q3 earnings per share of 47 cents, below consensus estimate of 52 cents.
select
2025-11-10
08:09:51
Voyager Therapeutics and Transition Bio Form Partnership for Drug Discovery
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03Businesswire
PinnedVectorY Receives FDA Clearance to Initiate PIONEER-ALS Trial for VTx-002
  • FDA Clearance: VectorY Therapeutics announced FDA approval to initiate the PIONEER-ALS Phase 1/2 trial for VTx-002, marking a significant milestone in the neurodegenerative disease landscape and potentially driving innovation in ALS treatment.
  • Targeted Therapy: VTx-002 is the first antibody therapy targeting TDP-43 pathology, aiming to reduce TDP-43 aggregation and restore normal cellular function, which could provide new treatment hope for over 5,000 new ALS patients diagnosed annually.
  • Clinical Trial Design: The trial will enroll 12 ALS patients to evaluate the safety and tolerability of VTx-002 while exploring ALS-related biomarkers, aiming to optimize the path for future clinical development.
  • Market Potential: ALS is a fatal neurodegenerative disease affecting over 30,000 patients, and the development of VTx-002 not only fills a critical treatment gap but also presents significant market opportunities to meet urgent medical needs.
[object Object]
Preview
9.0
11-26Benzinga
J&J Stops Alzheimer's Study as Drug Proves Ineffective in Slowing Disease Progression

  • Johnson & Johnson's Study Results: The Phase 2b AuTonomy study of posdinemab for early Alzheimer's disease did not achieve statistical significance in slowing clinical decline, leading to its discontinuation.

  • FDA Designation and Potential: Posdinemab received Fast Track designation from the FDA, showing potential to target phosphorylated tau in Alzheimer's patients, but its recent failure raises concerns for future Alzheimer's drug developments.

  • Novo Nordisk's Trial Findings: Novo Nordisk's phase 3 trials for semaglutide in early-stage Alzheimer's disease also failed to show superiority over placebo in reducing disease progression.

  • Market Reaction: Following the news, Johnson & Johnson's stock rose to a new 52-week high, trading at $206.99, reflecting investor sentiment despite the study setback.

[object Object]
Preview
7.5
11-10Newsfilter
Transition Bio and Voyager Team Up to Develop Small Molecules Aiming at TDP-43 for ALS and Frontotemporal Dementia

  • Collaboration Announcement: Transition Bio and Voyager Therapeutics have formed a partnership to develop small molecules targeting TDP-43 pathology in ALS and frontotemporal dementia (FTD), which are prevalent in neurodegenerative diseases.

  • Financial Terms: Transition Bio will lead the discovery and optimization of these small molecules, receiving an upfront payment and potential milestone payments totaling up to $500 million, along with royalties on net sales.

  • Technological Approach: Transition Bio's unique biomolecular condensate technology aims to selectively target toxic forms of TDP-43 without affecting its essential functions, addressing a significant challenge in treating these diseases.

  • Vision for Neurotherapeutics: Voyager's CEO emphasized the collaboration's alignment with their goal of building a diverse neurotherapeutic pipeline tailored to specific targets, leveraging expertise in ALS and FTD.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Voyager Therapeutics Inc (VYGR) stock price today?

The current price of VYGR is 4.35 USD — it has increased 2.84 % in the last trading day.

arrow icon

What is Voyager Therapeutics Inc (VYGR)'s business?

Voyager Therapeutics, Inc. is a biotechnology company engaged in leveraging the power of human genetics to modify the course of neurological diseases. The Company’s pipeline includes programs for Alzheimer’s disease, Friedreich’s ataxia, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of its programs are derived from its Tropism Redirection of AAV by Cell-type-specific Expression of RNA (TRACER) adeno-associated virus (AAV) capsid discovery platform, which is used to generate capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs includes Anti-Tau Antibody (VY7523), Tau Silencing Gene Therapy (VY1706), SOD1 Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program and others.

arrow icon

What is the price predicton of VYGR Stock?

Wall Street analysts forecast VYGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYGR is 13.57 USD with a low forecast of 8.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Voyager Therapeutics Inc (VYGR)'s revenue for the last quarter?

Voyager Therapeutics Inc revenue for the last quarter amounts to 13.37M USD, decreased -45.73 % YoY.

arrow icon

What is Voyager Therapeutics Inc (VYGR)'s earnings per share (EPS) for the last quarter?

Voyager Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, increased 193.75 % YoY.

arrow icon

What changes have occurred in the market's expectations for Voyager Therapeutics Inc (VYGR)'s fundamentals?

The market is revising Upward the revenue expectations for Voyager Therapeutics, Inc. (VYGR) for FY2025, with the revenue forecasts being adjusted by 11.98% over the past three months. During the same period, the stock price has changed by 2.59%.
arrow icon

How many employees does Voyager Therapeutics Inc (VYGR). have?

Voyager Therapeutics Inc (VYGR) has 172 emplpoyees as of December 05 2025.

arrow icon

What is Voyager Therapeutics Inc (VYGR) market cap?

Today VYGR has the market capitalization of 241.86M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free